PIK3CA and breast cancer: found that stage II and III breast cancers bearing a PIK3CA mutation, treated in a neoadjuvant setting with standard chemotherapy were associated with lower rates of pathological complete response (pCR), which could reflect chemoresistance in these tumors12.